Entrada Therapeutics, Inc. (TRDA) Stock Grade

About Entrada Therapeutics, Inc.'s fundamentals

Entrada Therapeutics is a biotechnology company with a market capitalization of $425.3 million that has experienced significant financial deterioration, with revenue declining 87.9% year-over-year and a net margin of -565.5%, indicating substantial losses relative to its revenue base. The company reported a net loss in its latest annual statement and does not pay a dividend. Given the steep revenue contraction and severe operating losses, traditional profitability metrics like P/E ratio and return on equity are not applicable.